Case finding for celiac disease (CD) is becoming increasingly common practice and is conducted in a wide range of clinical situations ranging from the presence of gastrointestinal symptoms to failure to thrive in children, prolonged fatigue, unexpected weight loss and anemia. Case finding is also performed in associated conditions, such as autoimmune thyroid disease, dermatitis herpetiformis and type 1 diabetes, as well as in patients with irritable bowel syndrome, unexplained neuropsychiatric disorders and first-degree relatives of patients with diagnosed CD. This aggressive active case finding has dramatically changed the clinical characteristics of newly diagnosed patients. For instance, higher numbers of patients who present with extraintestinal symptoms are now being diagnosed with CD. Current recommendations state that due to a high risk for complications if the disease remains undiagnosed, patients with extraintestinal symptoms due to CD require appropriate diagnosis and treatment. Despite criticism regarding the cost-effectiveness of case finding in CD, such an aggressive approach has been considered cost-effective for high-risk patients. The diagnosis of CD among patients with extraintestinal symptoms requires a high degree of awareness of the clinical conditions that carry a high risk for underlying CD. Also, understanding the correct use of specific serology and duodenal histology is key for an appropriate diagnostic approach. Both procedures combined are able to confirm diagnosis in the vast majority of cases. However, in certain circumstances, serology and even duodenal histology cannot confirm or rule out CD. A common cause of negative IgA serology is IgA deficiency. For such eventuality, IgG-based serological tests can help confirm the diagnosis. Importantly, some histologically diagnosed cases still remain seronegative despite exclusion of IgA deficiency. On the other hand, duodenal histology may be normal despite the presence of CD-specific antibodies and active CD. This has been clearly demonstrated in some cases of untreated dermatitis herpetiformis, but may also be due to the patchy condition of CD or lesions that are not adequately recognized by nonexpert endoscopists and/or pathologists. The effectiveness of agluten-free diet depends on the clinical end point addressed. A good example is the outcome of bone loss. While risk for fracture normalizes after the first year of dietary treatment, bone parameters measured by densitometry may not be normalized in the long-term follow-up. Moreover, it is still unclear how far an early gluten-free diet will positively affect associated autoimmune diseases like type 1 diabetes and autoimmune thyroiditis.

Keywords:
Celiac disease, Extraintestinal manifestations, Diagnosis
1.
Ludvigsson JF, Leffler DA, Bai JC, et al: The Oslo definitions for coeliac disease and related terms. Gut 2013;62:43-45.
2.
Ludvigsson JF, Bai JC, Biagi F, et al: Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210-1228.
3.
Rampertab SD, Pooran N, Brar P, et al: Trends in the presentation of celiac disease. Am J Med 2006;119:355.e9-e14.
4.
Groll A, Candy DC, Preece MA, et al: Short stature as the primary manifestation of coeliac disease. Lancet 1980;ii:1097-1099.
5.
Guandalini S, Assiri A: Celiac disease: a review. JAMA Pediatr 2014;168:272-278.
6.
Sanders DS, Evans KE, Hadjivassiliou M: Fatigue in primary care. Test for coeliac disease first? BMJ 2010;341:c5161.
7.
Rubio-Tapia A, Hill I, Ciaran PK, et al: ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease. Am J Gastroenterol 2013;108:656-676.
8.
Sainsbury A, Sanders DS, Ford AC: Meta-analysis: coeliac disease and hypertransaminasaemia. Aliment Pharmacol Ther 2012;34:33-40.
9.
Addolorato G, Leggio L, D'Angelo C, et al: Affective and psychiatric disorders in celiac disease. Dig Dis 2008;26:140-148.
10.
Rubio-Tapia A, Van Dyke CT, Lahr BD, et al: Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:983-987.
11.
Murray JA: Celiac disease in patients with an affected member, type 1 diabetes, iron-deficiency, or osteoporosis? Gastroenterology 2005;128:S52-S56.
12.
Halfdanarson TR, Litzow MR, Murray JA: Hematologic manifestations of celiac disease Blood 2007;109:412-420.
13.
Bottaro G, Cataldo F, Rotolo N, et al: The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastoenterol 1999;94:691-696.
14.
Brandimarte G, Tursi A, Giorgetti GM: Changing trends in clinical form of celiac disease. Which is now the main form of celiac disease in clinical practice? Minerva Gastroenterol Dietol 2002;48:121-130.
15.
Smukalla S, Lebwohl B, Mears JG, et al: How often do hematologists consider celiac disease in iron-deficiency anemia? Results of a national survey. Clin Adv Hematol Oncol 2014;12:100-105.
16.
Bergamaschi G, Markopoulos K, Albertini R, et al: Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. Haematologica 2008;93:1785-1791.
17.
Nelson EW, Ertan A, Brooks FP, et al: Thrombocytosis in patients with celiac sprue. Gastroenterology 1976;70:1042-1044.
18.
Caroccio A, Giannitrapani L, Di Prima L, et al: Extreme thrombocytosis as a sign of coeliac disease in the elderly; case report. Eur J Gastroenterol Hepatol 2002;14:897-900.
19.
Di Sabatino A, Rosado MM, Cazzola P, et al: Splenic hypo function and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 2006;4:179-186.
20.
Corazza GR, Frisoni M, Vaira D, et al: Effect of gluten-free diet on splenic hypofunction of adult coeliac disease. Gut 1983;24:228-230.
21.
Wang N, Truedsson L, Elvin K, et al: Serological assessment for celiac disease in IgA deficient adults. PLoS One 2014;9:e93180.
22.
Jameson B, Hollsing K, Magnusson S: Copper malabsorption in coeliac disease. Sci Total Environ 1985;42:29-36.
23.
Bonciolini V, Antiga E, Fabbri P, et al: Skin manifestations of celiac disease: not always dermatitis herpetiformis. Int J Dermatol 2014;53:e352-e353.
24.
Caproni M, Bonciolini V, D'Errico A, et al: Celiac disease and dermatologic manifestations: many skin clue to unfold gluten-sensitive enteropathy. Gastroenterol Res Pract 2012;2012:952753.
25.
Bolotin D, Petronic-Rosic V: Dermatitis herpetiformis. 1. Epidemiology, pathogenesis and clinical presentation. J Am Acad Dermatol 2011;64:4-11.
26.
Sugai E, Esmecuol E, Niveloni S, et al: Celiac disease serology in dermatitis herpetiformis. Which is the best option for detecting gluten sensitivity? Acta Gastroenterol Latinoam 2006;36:197-201.
27.
Michaelsson G, Gerden B, Ottosson M, et al: Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol 1993;129:667-673.
28.
Michaelsson G, Gerden B, Hagforsen E, et al: Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol 2000;142:44-51.
29.
Ojetti V, Aguilar Sanchez J, Guerriero C, et al: High prevalence of celiac disease in psoriasis. Am J Gastroenterol 2003;98:2574-2575.
30.
Ludvigsson JF, Lindelof B, Zingone F, et al: Psoriasis in a nationwide cohort study of patients with celiac disease. J Invest Dermatol 2011;131:2010-2016.
31.
Collin P, Reunala T: Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol 2000;4:13-20.
32.
Lehmann B: Role of the vitamin D3 pathway in healthy and diseased skin - facts, contradictions and hypotheses. Exp Dermatol 2009;18:97-108.
33.
Monteleone G, Pallone F, MacDonald TT, et al: Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond) 2010;120:1-11.
34.
Liu Y, Helms C, Liao W, et al: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041.
35.
Corazza GR, Andreani ML, Venturo N, et al: Celiac disease and alopecia areata: report of a new association. Gastroenterology 1995;109:1333-1337.
36.
Ertekin V, Tosun MS, Erdem T: Screening of celiac disease in children with alopecia areata. Indian J Dermatol 2014;59:317.
37.
Fessatou S, Kostaki M, Karpathios T: Celiac disease and alopecia areata in childhood. J Pediatr Child Health 2003;39:152-154.
38.
Bardella MT, Marino R, Barbareschi M, et al: Alopecia areata and coeliac disease: no effect of a gluten-free diet on hair growth. Dermatology 2000;200:108-110.
39.
Bondavalli P, Quadri G, Parodi A, et al: Failure of gluten-free diet in celiac disease-associated alopecia areata. Acta Derm Venereol 1998;78:319.
40.
Ress K, Annus T, Putnik U, et al: Celiac disease in children with atopic dermatitis. Pediatr Dermatol 2014;31:483-488.
41.
Ciacci C, Cavallaro R, Iovino P, et al: Allergy prevalence in adult celiac disease. J Allergy Clin Immunol 2004;113:1199-1203.
42.
Slebioda Z, Szponar E, Kowalska A: Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review. Arch Immunol Ther Exp (Warsz) 2014;62:205-215.
43.
Yaşar S, Yaşar B, Abut E, et al: Clinical importance of celiac disease in patients with recurrent aphthous stomatitis. Turk J Gastroenterol 2012;23:14-18.
44.
Corazza GR, Di Stefano M, Mauriño E, et al: Bones in coeliac disease: diagnosis and treatment. Best Pract Res Clin Gastroenterol 2005;19:453-465.
45.
Sánchez MI, Mohaidle A, Baistrocchi A, et al: Risk of fracture in celiac disease: gender, dietary compliance, or both? World J Gastroenterol 2011;17:3035-3042.
46.
Olmos M, Antelo M, Vazquez H, et al: Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig Liver Dis 2008;40:46-53.
47.
Bushara KO, et al: Neurologic presentation of celiac disease. Gastroenterology 2005;128:S92-S97.
48.
Hadjivassiliou M, Sanders DS, Grünewald RA, et al: Gluten sensitivity: from gut to brain. Lancet Neurol 2010;9:318-330.
49.
Hadjivassiliou M, Sanders DS, Woodroofe N, et al: Gluten ataxia. Cerebellum 2008;7:494-498.
50.
Luostarinen L, Pirttila T, Collin P: Coeliac disease presenting with neurological disorders. Eur Neurol 1999;42:132-135.
51.
Luostarinen L, Himanen SL, Luostarinen M, et al: Neuromuscular and sensory disturbances in patients with well treated celiac disease. J Neurol Neurosurg Psychiatry 2003;74:490-494.
52.
Kaplan JG, Pack D, Horoupian D, et al: Distal axonopathy associated with chronic gluten enteropathy: a treatable disorder. Neurology 1988;38:642-645.
53.
Gobbi G, Furio B, et al: Coeliac disease, epilepsy, and cerebral calcifications. Lancet 1992;340;439-443.
54.
Molteni N, Bardella MT, Baldassarri AR, et al: Celiac disease associated with epilepsy and intracranial calcifications: report of two patients. Am J Gastroenterol 1988;83:992-994.
55.
Johnson A, Dale R, Wienholt L, et al: Coeliac disease, epilepsy, and cerebral calcifications: association with TG6 autoantibodies. Develop Med Child Neurol 2013;55:90-93.
56.
Gobbi G: Celiac disease, epilepsy and cerebral calcifications. Brain Dev 2005;27:189-200.
57.
Dimitrova AK, Ungaro RC, Lebwohl B, et al: Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 2013;53:344-355.
58.
Gabrielli M, Cremonini F, Fiore G, et al: Association between migraine and celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol 2003;98:625-629.
59.
Roche Herrero MC, Arcas Martínez J, Martínez-Bermejo A, et al: The prevalence of headache in a population of patients with coeliac disease. Rev Neurol 2001;32:301-309.
60.
Goldberg D: A psychiatric study of patients with diseases of the small intestine. Gut 1970;11:459-465.
61.
Addolorato G, Stefanini GF, Capristo E, et al: Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality ‘trait' or a reactive illness? Hepatogastroenterology 1996;43:1513-1517.
62.
Häuser W, Janke KH, Klump B, et al: Anxiety and depression in adult patients with celiac disease on a gluten-free diet. World J Gastroenterol 2010;16:2780.
63.
Smith D, Gerdes L: Meta-analysis on anxiety and depression in adult celiac disease. Acta Psychiatr Scand 2012;125:183-193.
64.
Zingone F, Siniscalchi M, Capone P, et al: The quality of sleep in patients with coeliac disease. Aliment Pharmacol Ther 2010;32:1031-1036.
65.
Siniscalchi M, Iovino P, Tortora R, et al: Fatigue in adult coeliac disease. Aliment Pharmacol Ther 2005;22:489-494.
66.
Nachman F, del Campo MP, González A, et al: Long-term deterioration of quality of life in adult patients with celiac disease is associated with treatment noncompliance. Dig Liver Dis 2010;42:685-691.
67.
Ferretti A, Parisi P, Villa MP: The role of hyperhomocysteinemia in neurological features associated with coeliac disease. Med Hypotheses 2013;81:524-531.
68.
Carta MG, Hardoy MC, Boi MF, et al: Association between panic disorder, major depressive disorder and celiac disease: a possible role of thyroid autoimmunity. J Psychosom Res 2002;53:789-793.
69.
Garud S, Leffler D, Dennis M, et al: Interaction between psychiatric and autoimmune disorders in coeliac disease patients in the Northeastern United States. Aliment Pharmacol Ther 2009;29:898-905.
70.
Van Hees NJ, Van der Does W, Giltay EJ: Coeliac disease, diet adherence and depressive symptoms. J Psychosom Res 2013;74:155-160.
71.
Skowera A, Peakman M, Cleare A, et al: High prevalence of serum markers of coeliac disease in patients with chronic fatigue syndrome. J Clin Pathol 2001;54:335-336.
72.
Barratt SM, Leeds JS, Sanders DS: Factors influencing the type, timing and severity of symptomatic responses to dietary gluten in patients with biopsy-proven coeliac disease. J Gastrointest Liver Dis 2013;22:391-396.
73.
Pulido O, Zarkadas M, Dubois S, et al: Clinical features and symptom recovery on a gluten-free diet in Canadian adults with celiac disease. Can J Gastroenterol 2013;27:449-453.
74.
Rodrigo L, Blanco I, Bobes J, et al: Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study. Arthritis Res Ther 2014;16:421.
75.
Herfarth HH, Martin CF, Sandler RS, et al: Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2014;20:1194-1197.
76.
Ludvigsson JF, Elfström P, Broomé U: Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 2007;5:63-69.
77.
Sainsbury A, Sanders DS, Ford AC, et al: Meta-analysis: coeliac disease and hypertransaminasemia. Aliment Pharmacol Ther 2011;34:33-34.
78.
Zanini B, Baschè R, Ferraresi A, et al: Factors that contribute to hypertransaminasemia in patients with celiac disease or functional gastrointestinal syndromes. Clin Gastroenterol Hepatol 2014;12:804-810.
79.
Tersigni C, Castellani R, de Waure C, et al: Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. Hum Reprod Update 2014;20:582-593.
80.
Smecuol E, Mauriño E, Vazquez H, et al: Gynaecological and obstetric disorders in coeliac disease: frequent clinical onset during pregnancy or the puerperium. Eur J Gastroenterol Hepatol 1996;8:63-69.
81.
Lasa JS, Zubiaurre I, Soifer LO: Risk of infertility in patients with celiac disease: a meta-analysis of observational studies. Arq Gastroenterol 2014;51:144-150.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.